SVN-015
Alcohol Use Disorder (AUD)
Key Facts
About Solvonis Therapeutics
Solvonis Therapeutics is an emerging biopharma focused on developing novel treatments for high-burden CNS disorders, starting with Alcohol Use Disorder and PTSD. The company has achieved key preclinical milestones, including the selection of a lead candidate (SVN-114) for PTSD and the expansion of SVN-015 into depression, supported by recent U.S. patent allowances. Its strategy involves building a targeted pipeline through internal discovery programs, aiming to address substantial unmet medical needs with significant market potential, while navigating the challenges of a pre-revenue, public company in a nascent sector.
View full company profileAbout Solvonis Therapeutics
Solvonis Therapeutics is an emerging biopharma focused on developing novel treatments for high-burden CNS disorders, starting with Alcohol Use Disorder and PTSD. The company has achieved key preclinical milestones, including the selection of a lead candidate (SVN-114) for PTSD and the expansion of SVN-015 into depression, supported by recent U.S. patent allowances. Its strategy involves building a targeted pipeline through internal discovery programs, aiming to address substantial unmet medical needs with significant market potential, while navigating the challenges of a pre-revenue, public company in a nascent sector.
View full company profileTherapeutic Areas
Other Alcohol Use Disorder (AUD) Drugs
| Drug | Company | Phase |
|---|---|---|
| KT-110 | Kinnov Therapeutics | Phase 2 |
| KT-110 (New Galenic Form) | Kinnov Therapeutics | Formulation Testing |
| TMP-301 | Tempero Bio | Phase 1 |
| iSTEP-N | Akyso Therapeutics | Pre-clinical |
| ANS-858 | Amygdala Neurosciences | Preclinical |
| Varenicline/Bupropion Combination | Sobrera Pharma | Phase 2 |
| TNX-102 SL | Tonix Pharmaceuticals | Phase 2 |